Bridging the Valley of Death of therapeutics for neurodegeneration

Nat Med. 2010 Nov;16(11):1227-32. doi: 10.1038/nm.2222. Epub 2010 Sep 21.


Neurodegenerative diseases are the sixth leading cause of death in the US. The market for disease-modifying drugs is enormous, but no drug exists. Academic scientists are increasingly pursuing the discovery and development of therapeutics. Their progress could potentially reduce the risk of failure sufficiently to warrant greater industry investment and movement of leads into clinical trials. Here we consider the many obstacles to the development of therapeutics for neurodegenerative disease within academia, with a special focus on organizational issues.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Biomarkers / metabolism
  • Cooperative Behavior
  • Cultural Diversity
  • Drug Industry
  • Humans
  • Intellectual Property
  • Nerve Degeneration / therapy*
  • Translational Research, Biomedical*
  • Universities


  • Biomarkers